Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CNS Pharmaceuticals, Inc. - Common Stock (NQ:CNSP)

0.9029 -0.0046 (-0.51%)
Streaming Delayed Price Updated: 9:39 AM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about CNS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
European Clinical Trial Site Expansion for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Brain Cancer Drug Candidate Drives Patient Enrollment
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Seeking to Solve Unmet Need for GBM Treatment
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Announces First European Dosing in Potentially Pivotal GBM Trial
Via Investor Brand Network
Implanted Pump Holds Promise in Treating Brain Cancer
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) CEO Participated in The American Brain Tumor Association’s Breakthrough for Brain Tumors(R) 5K Run Following European Clinical Trial Site Activations
Via Investor Brand Network
Researchers Turn to AI for Insights on Treating Brain Tumors
Via Investor Brand Network
Topics Artificial Intelligence
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Q3 2022 Financial Numbers, Corporate Update
Via Investor Brand Network
Scientists Look for Ways to Disable Sugar Molecule That Fuels Cancer Persistence
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Maintains Focus on Advancing Clinical Development Program for Lead Drug Candidate, Berubicin
Via Investor Brand Network
Research Finds New Therapy Path for Brain Cancer
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Maintains Strong Cash Position as It Continues Drug Development Program Pursuing Treatment for GBM
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Targeted ‘Finish Line Is Within Sight’ as It Pursues Potential GBM Treatment
Via Investor Brand Network
New Brain Cancer Clinical Trial Platform Launched in Australia
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Doses First Patient in Global Berubicin Trial Evaluating GBM Treatment
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Shows Superior Performance to Other Anthracyclines, Standards of Care for GBM
Via Investor Brand Network
Researchers Discover New Way to Noninvasively Monitor Immune Cells Inside Tumors
Via Investor Brand Network
Patient Plays Sax During Lengthy Surgery to Remove Brain Tumor
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Anticipating 2023 IND Application for Secondary Portfolio Candidate
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Executes on Several Clinical, Operational Advancements in Pursuit of GBM Treatment
Via Investor Brand Network
Researchers Uncover Vital Clues on Drivers Behind Growth, Size of Brain Tumors
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Participate in Breakthrough for Brain Tumors(R) 5K Run
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Advancement of Berubicin Clinical Trial Featured in Syndicated Broadcast
Via Investor Brand Network
New Laws on Abortion May Complicate Cancer Treatment for Pregnant Patients
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Poised to Bring ‘Potentially Impactful’ Therapy to GBM Patients
Via Investor Brand Network
UC San Diego Offers New Radiation Therapy That Prevents Tumor Regrowth
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Activates First European Sites for Potentially Pivotal Clinical Trial
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Virtual Investor Innovations in Oncology Event
Via Investor Brand Network
Study Finds That Endometriosis Prognosis Worsens as CNS Metastasis Occurs
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Participates in H.C. Wainwright 24th Annual Global Investment Conference, Presenting Key Investor Highlights on Novel Anthracycline Berubicin for GBM Treatment
Via Investor Brand Network
TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Leading Charge to Find Potential Treatment Option for GBM
Via Investor Brand Network
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.